TRCT
AXSM icon

Tower Research Capital (TRC)’s Axsome Therapeutics AXSM Stock Holding History

Tower Research Capital (TRC)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Sell
1,181
-591
-33% -$102K 0.01% 1617
2025
Q4 		$324K Buy
1,772
+1,010
+133% +$141K 0.01% 1099
2025
Q3 		$92.5K Sell
762
-3,118
-80% -$351K ﹤0.01% 2052
2025
Q2 		$405K Buy
3,880
+2,999
+340% +$318K 0.01% 1161
2025
Q1 		$102K Sell
881
-3,692
-81% -$421K ﹤0.01% 1758
2024
Q4 		$387K Buy
4,573
+3,931
+612% +$361K 0.01% 1239
2024
Q3 		$57.7K Sell
642
-3,941
-86% -$344K ﹤0.01% 2646
2024
Q2 		$369K Buy
4,583
+3,703
+421% +$274K 0.01% 1588
2024
Q1 		$70.2K Sell
880
-5,646
-87% -$474K ﹤0.01% 2051
2023
Q4 		$519K Buy
6,526
+5,955
+1,043% +$398K 0.01% 1340
2023
Q3 		$39.9K Sell
571
-422
-42% -$31.5K ﹤0.01% 2742
2023
Q2 		$71.4K Buy
993
+178
+22% +$13.1K ﹤0.01% 2291
2023
Q1 		$50K Buy
815
+477
+141% +$31.3K ﹤0.01% 2490
2022
Q4 		$27K Sell
338
-25,953
-99% -$1.55M ﹤0.01% 2830
2022
Q3 		$1.17M Buy
26,291
+24,995
+1,929% +$1.25M 0.02% 638
2022
Q2 		$50K Buy
1,296
+816
+170% +$25.8K ﹤0.01% 2871
2022
Q1 		$20K Sell
480
-571
-54% -$17.7K ﹤0.01% 3521
2021
Q4 		$40K Sell
1,051
-644
-38% -$23.7K ﹤0.01% 2937
2021
Q3 		$56K Buy
1,695
+159
+10% +$6.2K ﹤0.01% 2854
2021
Q2 		$103K Sell
1,536
-2,586
-63% -$155K ﹤0.01% 2394
2021
Q1 		$234K Buy
4,122
+3,082
+296% +$217K ﹤0.01% 1883
2020
Q4 		$85K Sell
1,040
-13,966
-93% -$1.04M ﹤0.01% 2508
2020
Q3 		$1.07M Buy
15,006
+10,781
+255% +$840K 0.01% 920
2020
Q2 		$348K Buy
+4,225
New +$325K 0.01% 1323
2020
Q1 		– Sell
-147
Closed -$15K – 3038
2019
Q4 		$15K Sell
147
-3,776
-96% -$153K ﹤0.01% 2089
2019
Q3 		$80K Sell
3,923
-9,429
-71% -$242K 0.01% 1481
2019
Q2 		$344K Buy
+13,352
New +$268K 0.02% 635
2019
Q1 		– Sell
-888
Closed -$3K – 3779
2018
Q4 		$3K Buy
+888
New +$2.92K ﹤0.01% 3146
2018
Q3 		– Sell
-1,059
Closed -$3K – 3748
2018
Q2 		$3K Sell
1,059
-1,638
-61% -$5.08K ﹤0.01% 3206
2018
Q1 		$7K Buy
2,697
+2,452
+1,001% +$7.34K ﹤0.01% 2581
2017
Q4 		$1K Buy
+245
New +$1.24K ﹤0.01% 3321
2017
Q2 		– Sell
-4,170
Closed -$16K – 2696
2017
Q1 		$16K Buy
+4,170
New +$19.9K ﹤0.01% 1425
2016
Q3 		– Sell
-481
Closed -$4K – 3622
2016
Q2 		$4K Sell
481
-220
-31% -$2.03K ﹤0.01% 3494
2016
Q1 		$6K Buy
701
+377
+116% +$3.46K ﹤0.01% 2497
2015
Q4 		$3K Buy
+324
New +$2.85K ﹤0.01% 3389

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s AXSM Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Axsome Therapeutics (AXSM) stake by 33% in Q1 2026, selling an estimated $102K and leaving 1,181 shares worth $200K. The position accounts for 0.01% of the portfolio, ranked #1617.

Tower Research Capital (TRC) first reported a position in AXSM in Q4 2015 and has held it in 35 quarters since. The position peaked at $1.17M in Q3 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Tower Research Capital (TRC) held 1,181 shares of Axsome Therapeutics worth $200K as of Q1 2026.
  • Tower Research Capital (TRC) sold 591 Axsome Therapeutics shares in Q1 2026, an estimated $102K.
  • Axsome Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1617 holding.
  • Tower Research Capital (TRC) first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 35 quarters since.
  • Tower Research Capital (TRC)'s Axsome Therapeutics position peaked at $1.17M in Q3 2022.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.